IntegraGen is conducting groundbreaking research in the area of oncology biomarkers and the development of an advanced scientific software program that will aid in the interpretation of genome sequencing data obtained from cancer patients. Click here for the latest updates on our progress.

IntegraGen’s Scientific Advisory Board Meets to Review latest miR-31-3p data

IntegraGen’s oncology Scientific Advisory Board (SAB) recently met at the venue of the 2016 American Society of Oncology’s (ASCO) Gastrointestinal Cancers Symposium in San Francisco to review the results from the latest clinical study exploring the predictivity of miR-31-3p on the efficacy of anti-EGFR therapy in all-RAS wild-type metastatic colorectal cancer (…)  » 

IntegraGen presents positive data from two new studies on miR-31-3p biomarker at ASCO 2015

colorectal-cancer-intgragen-biomarker-mir-31-3p

Results from two new studies exploring the role of the microRNA biomarker miR-31-3p in patients with metastatic colorectal cancer were presented during the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting. The studies reported positive results on the association between miR-31-3p expression and clinical outcomes in metastatic colorectal cancer (mCRC) patients treated with (…)  » 

miR-31-3p oncology biomarker data to be presented at ASCO 2015

Data from two studies reporting results from clinical studies with IntegraGen’s miR-31-3p biomarker is scheduled to be presented during the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago on May 29 through June 2, 2015.

The first study will report results from research conducted in cooperation (…)  » 

Funding of HECAM Project for Liver Cancer

IntegraGen is pleased to announce funding from  BPIFrance for the HECAM project which is aimed to improve screening, diagnosis and treatment of liver cancer with an emphasis on hepatocellular carcinoma (HCC).

BPIFrance will provide 18.2 million euros to fund the project. The initiative will be led by GE Healthcare and (…)  »